Corcept Therapeutics Incorporated (NASDAQ: CORT) is a Menlo Park, California-headquartered specialty biopharmaceutical company focused on discovery and development of drugs that modulate cortisol activity — a single-mechanism focus that has driven a two-decade build into a profitable mid-cap biopharma. The company was co-founded in 1998 by Joseph Belanoff (a Stanford-trained psychiatrist) and Alan Schatzberg (a renowned psychiatry researcher) with the hypothesis that excess cortisol signaling drives a range of serious diseases (Cushing syndrome — the obvious one — but also psychiatric depression, oncology adjuncts, metabolic disease, others), and that selectively modulating the glucocorticoid receptor (GR) could provide therapeutic benefit. Belanoff has been CEO since founding — an unusually long-tenured biotech leader. Corcept's only marketed product is Korlym (mifepristone) — a non-selective cortisol-receptor antagonist (also a progesterone antagonist — the abortifacient label restriction is a meaningful commercial constraint) — FDA-approved February 2012 for hyperglycemia secondary to endogenous Cushing syndrome in adults with T2DM or glucose intolerance who have failed surgery or are not candidates for surgery. Korlym has scaled into a ~$700M+ annual franchise growing ~10-15% annually for a decade through patient-finder initiatives Corcept funds at endocrinologist offices, prescriber education, and disciplined pricing. The company has invested heavily in the relacorilant pipeline — a next-generation selective glucocorticoid antagonist designed to avoid mifepristone's progesterone-receptor effects — with two Phase 3 programs: GRACE Cushing trial (NDA filed/under FDA review, potential approval that would replace Korlym) and ROSELLA platinum-resistant ovarian-cancer trial (the headline pipeline binary). Capital structure net-cash with no debt and aggressive shareholder-return allocation. CORT enters FY2026 with FY2025 revenue selected various aggregate ~$740-820M (~12-15% growth), aggregate adjusted EPS ~$1.30-1.65, adjusted EBITDA ~$160-220M, under co-founder/CEO Joseph Belanoff. The first thesis pillar is the Korlym franchise — entirety of commercial revenue (~$700M+ annually) and the funding engine for relacorilant: Korlym (mifepristone) is a small-molecule oral antagonist of the glucocorticoid receptor blocking cortisol's effects at receptor level; FDA-approved 2012 for hyperglycemia secondary to endogenous Cushing syndrome in adults with T2DM/glucose intolerance failed/non-candidates for surgery; mifepristone also a progesterone-receptor antagonist (hence its better-known use as abortifacient Mifeprex at higher doses) — progesterone activity creates label restriction (black-box on termination of pregnancy, not used in fertile women without contraception) limiting commercial breadth; endogenous Cushing syndrome is rare — ~20-30K+ US patients diagnosed (likely many more undiagnosed) — chronic excess cortisol driving weight gain, hyperglycemia, hypertension, mood changes, osteoporosis — diagnosis challenging, patients presenting to endocrinologists/psychiatrists/PCPs with non-specific symptoms (depression, T2DM, hypertension) and cortisol dysregulation missed for years; patient-finder initiative funds endocrinologist screening programs (genetic testing, cortisol protocols, clinical screening) identifying previously-undiagnosed patients — multi-year growth driver; commercial model — high-priced specialty drug (~$120-180K+ patient-year), ~95%+ gross margins, dedicated rare-disease salesforce, payer management; FY2025 dynamics are Korlym revenue ~12-15% growth (patient adds + pricing), prescriber base expanding, gross margin very high, operating leverage (R&D growing on relacorilant but ahead of commercial costs); FY2026 catalyst is continued patient adds (~10-15% pattern), relacorilant Cushing NDA decision (if approved, transition Cushing patients to relacorilant — major franchise upgrade with cleaner safety, no abortifacient restriction, expanded breadth, extended IP), generic-mifepristone dynamics (Teva and others launched generics — though rare-disease specialty channel mitigates), pipeline progression; risks/competitors are generic mifepristone overhang, relacorilant transition risk (transition discount could compress revenue temporarily), broader Cushing landscape — Recordati's Isturisa (osilodrostat) for Cushing-disease pituitary form, older generics (ketoconazole, etomidate, metyrapone), Crinetics (CRNX, Cushing pipeline), Xeris Biopharma (XERS); comp set Recordati (REC.MI), Crinetics (CRNX), Strongbridge/Xeris (XERS), Sparrow Pharmaceuticals (private), and specialty Insmed (INSM), Vanda (VNDA), Argenx (ARGX), Ultragenyx (RARE). The second pillar is the relacorilant pipeline — next-generation cortisol modulator: relacorilant is oral once-daily selective glucocorticoid antagonist blocking GR without antagonizing PR (eliminating progesterone-related effects constraining mifepristone); GRACE Phase 3 trial — randomized placebo-controlled in adults with endogenous Cushing syndrome with hyperglycemia and/or hypertension — positive top-line (statistically significant on glucose, BP, weight + clean safety), NDA filed, FDA review with potential 2026 PDUFA decision — if approved relacorilant becomes franchise-defining (replacing Korlym, IP protection extending well into 2030s+); ROSELLA Phase 3 trial — relacorilant + nab-paclitaxel vs nab-paclitaxel monotherapy in platinum-resistant ovarian cancer — tough setting where new active agents scarce, mechanism rationale that glucocorticoid signaling promotes taxane resistance and relacorilant GR antagonism re-sensitizes — Phase 2 showed encouraging PFS — registrational with data readout expected 2026 (transformatively expands TAM if positive); other pipeline — relacorilant in other oncology, dazucorilant (ALS), additional cortisol-modulator molecules in earlier-stage metabolic/neurology/oncology; FY2025 dynamics are GRACE NDA under review, ROSELLA completing/maturing, earlier-stage progressing, R&D intense; FY2026 catalyst is GRACE NDA decision (likely first H1 2026 PDUFA — major near-term commercial), ROSELLA readout (major asymmetric pipeline-value event), pipeline progression, possible BD activity; risks are ROSELLA failure (mixed Phase 2 + tough setting — meaningful risk), GRACE setback (FDA additional info), relacorilant-transition execution from Korlym, pipeline risk, capital-allocation discipline; comp set: relacorilant has no late-stage selective GR antagonist competitor, Cushing comps Recordati (REC.MI), Crinetics (CRNX), PROC oncology GSK (GSK Zejula), AstraZeneca (AZN Lynparza), Genentech (Tecentriq), AbbVie (ABBV — ImmunoGen Elahere); broader specialty Insmed (INSM), Krystal (KRYS), Argenx (ARGX), Ultragenyx (RARE). The capital story: net-cash shareholder-return-rich (unusual for specialty biopharma) — no dividend (cash to R&D + pipeline + buybacks), aggressive opportunistic buybacks (share count down from ~120M+ to ~100-105M, multi-year programs consistently executed), substantial net cash ~$450-600M+ (no meaningful debt — historically debt-free), excellent FCF conversion (Korlym high-margin specialty + low SG&A), capital priorities fund R&D (relacorilant Phase 3 + pipeline) → aggressive buybacks → maintain net cash → possible bolt-on M&A or BD, with relacorilant-driven R&D pace, cash deployment, and eventual Korlym-to-relacorilant transition as principal considerations. At ~$50-100 per share on ~100-105M shares (~$5-10B equity, ~$4.5-9.5B EV given net-cash) CORT trades at roughly ~30-65x P/E (broad range — non-GAAP vs GAAP + binary pipeline), ~25-50x EV/EBITDA — premium specialty-pharma multiple reflecting relacorilant pipeline optionality (esp. ROSELLA) + Korlym franchise persistence + IP-extension via relacorilant + strong balance sheet — versus Recordati (REC.MI), Crinetics (CRNX), Xeris (XERS) in Cushing; Insmed (INSM), Vanda (VNDA), Argenx (ARGX), Ultragenyx (RARE), Krystal (KRYS), BridgeBio (BBIO), Apellis (APLS) in specialty; GSK (GSK), AstraZeneca (AZN), AbbVie (ABBV) in PROC oncology. FY2026 base case: ~$840-940M+ revenue + ~$1.50-1.95 adj. EPS + Korlym continued growth + relacorilant Cushing NDA decision pending + ROSELLA readout binary + continued buybacks + cash building; bull case: ~$900-1.05B+ revenue + ~$1.75-2.40+ adj. EPS on relacorilant Cushing approved + ROSELLA positive (transformative oncology) + Korlym continued growth + modest generic impact + aggressive buybacks + possible accretive M&A + substantial re-rating; bear case: ~$650-760M revenue + ~$0.85-1.25 adj. EPS on ROSELLA failure (major asymmetric downside — eliminates oncology optionality) + GRACE setback (delaying transition) + accelerated generic-mifepristone share losses + pipeline setbacks + compression. The thesis depends on the Korlym commercial pipeline (Cushing patient identification + prescription growth + generic defense + relacorilant transition prep) plus the relacorilant pipeline (GRACE approval + ROSELLA readout + IP extension + indication exploration) plus net-cash balance sheet plus aggressive buybacks plus Joseph Belanoff's multi-decade co-founder stewardship of the cortisol-modulator platform.

[CORT] Corcept Therapeutics Thesis 2026: Korlym Funds a Next-Generation Cortisol Modulator Across Cushing's and Cancer

Key Takeaways

Corcept Therapeutics Incorporated (NASDAQ: CORT) is expected to close FY2025 with selected various aggregate revenue of roughly $740-820M (~12-15% growth) and aggregate adjusted EPS in the area of $1.30-1.65 (GAAP EPS lower at ~$0.75-1.00 on heavy R&D investment), with adjusted EBITDA selected various aggregate ~$160-220M, under President & CEO Joseph Belanoff (~27+ year tenure as co-founder/CEO since 1998 — one of the longest-tenured biotech CEOs).
The first deep-dive — the Korlym (mifepristone) commercial franchise for endogenous Cushing syndrome — covers the company's only-marketed product Korlym (a cortisol-receptor antagonist) — selected various aggregate ~$700M+ annual revenue, growing on diagnosed-Cushing-patient expansion + neuropsychiatric/rare-disease-specialist prescriber education + selected price actions, with the patient-finder initiative (genetic-and-clinical screening protocols Corcept funds for endocrinologists) driving incremental NIW; FY2026 catalyst is Korlym prescription growth, the relacorilant transition (Corcept's next-generation selective glucocorticoid antagonist that could replace Korlym), and competitive entry from generic mifepristone (a structural overhang).
The second deep-dive — the relacorilant pipeline (Cushing's transition + the ROSELLA Phase 3 ovarian-cancer readout) — covers Corcept's selective glucocorticoid antagonist relacorilant in (a) the GRACE Phase 3 trial for endogenous Cushing syndrome (positive top-line, NDA filed/under FDA review, potential 2026 approval that would replace Korlym as the leading franchise asset — relacorilant has a cleaner safety profile, no abortifacient label restriction, and substantially expanded commercial breadth) and (b) the ROSELLA Phase 3 trial of relacorilant + nab-paclitaxel in platinum-resistant ovarian cancer (a major data readout expected — a positive result would open a multi-billion-dollar oncology indication and transformatively expand Corcept's TAM); FY2026 catalyst is the relacorilant Cushing NDA decision and the ROSELLA Phase 3 readout (both major binary events).
Capital position is net-cash and shareholder-return-trajectory: no dividend (and not near-term), aggressive opportunistic buybacks (the diluted share count has fallen from selected various aggregate ~120M+ toward ~100-105M), substantial net cash (selected various aggregate ~$450-600M+ of cash and short-term investments with no meaningful debt), no leverage of consequence, and ~100-105M shares outstanding (declining).
FY2026 catalysts: Korlym continued growth, relacorilant Cushing NDA decision (potential approval — a major franchise upgrade event), ROSELLA Phase 3 ovarian-cancer readout (a major asymmetric upside binary), generic-mifepristone competitive dynamics (a structural overhang on Korlym), broader pipeline programs (other cortisol-modulator indications — metabolic, oncology, neurology), continued aggressive buybacks compounding EPS, and possible bolt-on M&A or business-development activity.

Company Background

Corcept Therapeutics Incorporated, headquartered in Menlo Park, California, is a specialty biopharmaceutical company focused on the discovery and development of drugs that modulate the activity of cortisol — a single-mechanism focus that has driven the company's two-decade build into a profitable mid-cap biopharma. The company was co-founded in 1998 by Joseph Belanoff (a Stanford-trained psychiatrist) and Alan Schatzberg (a renowned psychiatry researcher) with the hypothesis that excess cortisol signaling drives a range of serious diseases (Cushing syndrome — the obvious one — but also psychiatric depression, oncology adjuncts, metabolic disease, and others), and that selectively modulating the glucocorticoid receptor (GR) could provide therapeutic benefit. Belanoff has been CEO since founding — an unusually long-tenured biotech leader. Corcept's only marketed product is Korlym (mifepristone) — a non-selective cortisol-receptor antagonist (also a progesterone antagonist — the "abortifacient" label restriction is a meaningful commercial constraint) — FDA-approved in February 2012 for the treatment of hyperglycemia secondary to endogenous Cushing syndrome in adults with type 2 diabetes mellitus or glucose intolerance who have failed surgery or are not candidates for surgery. Korlym has scaled into a selected various aggregate ~$700M+ annual revenue franchise — growing at ~10-15% annually for a decade — through (a) patient identification (Corcept funds endocrinologist programs that identify previously-undiagnosed Cushing patients via genetic and clinical screening), (b) prescriber education (working with endocrinologists, neuropsychiatrists, rare-disease specialists to expand the prescriber base), and (c) disciplined pricing. The company has invested heavily in the relacorilant pipeline — a next-generation selective glucocorticoid antagonist designed to avoid mifepristone's progesterone-receptor effects (allowing broader commercial use without the abortifacient restriction) — with two Phase 3 programs: the GRACE Cushing trial (NDA filed/under FDA review, potential approval that would replace Korlym) and the ROSELLA platinum-resistant ovarian-cancer trial (the headline pipeline binary). Capital structure is net-cash with no debt and aggressive shareholder-return capital allocation. Risks: generic-mifepristone competition (Teva and others have launched generic mifepristone — a structural commercial overhang on Korlym, though the rare-disease use is the smaller piece of total mifepristone consumption), the relacorilant Phase 3 readouts (GRACE + ROSELLA — major binary catalysts), regulatory/FDA approval pathway uncertainty, pipeline-development risk in newer indications, and the long-tail Belanoff-succession question (he's been CEO for 27+ years).

The Korlym Commercial Franchise for Cushing Syndrome

Korlym is the entirety of Corcept's commercial revenue — selected various aggregate ~$700M+ annually — and the funding engine for the relacorilant pipeline. Korlym (mifepristone): a small-molecule oral antagonist of the glucocorticoid receptor (GR) — the receptor cortisol activates to drive its physiological and pathological effects — that blocks cortisol's effects at the receptor level; FDA-approved in 2012 for hyperglycemia secondary to endogenous Cushing syndrome in adults with T2DM or glucose intolerance who have failed surgery or are not candidates for surgery; mifepristone is also a progesterone-receptor antagonist (hence its better-known use as the abortifacient drug Mifeprex/Korlym at higher doses) — the progesterone activity creates a commercial label restriction (Korlym carries a black-box warning about termination of pregnancy and is not used in fertile women without contraception) and a regulatory complexity that limits commercial breadth. Endogenous Cushing syndrome is a rare disease — selected various aggregate ~20,000-30,000+ US patients with diagnosed disease (and likely many more undiagnosed) — characterized by chronic excess cortisol driving weight gain, hyperglycemia, hypertension, mood changes, osteoporosis, and other manifestations; diagnosis is challenging, with patients often presenting first to endocrinologists, neuropsychiatrists, or primary care with non-specific symptoms (depression, T2DM, hypertension) and the underlying cortisol dysregulation missed for years. The patient-finder initiative: Corcept funds screening programs at endocrinologist offices (genetic testing, cortisol measurement protocols, clinical screening) to identify previously-undiagnosed Cushing patients — these initiatives drive incremental new patient starts and have been a multi-year growth driver. The commercial model: high-priced specialty drug (selected various aggregate ~$120-180K+ per patient-year), 95%+ gross margins, dedicated rare-disease salesforce, payer-management. FY2025 dynamics: Korlym revenue growing ~12-15% (patient adds + pricing), prescriber base expanding via patient-finder programs and education, gross margin extremely high, operating leverage (R&D spend growing on relacorilant but ahead of commercial-cost growth). FY2026 catalyst: continued patient adds and prescription growth (the multi-year ~10-15% growth pattern), the relacorilant Cushing NDA decision (if approved, Corcept will transition Cushing patients from Korlym to relacorilant — a major franchise upgrade — relacorilant is a selective GR antagonist without progesterone effects, eliminating the abortifacient label restriction and opening a much broader commercial profile, plus presumably extending IP protection well into the 2030s+), generic-mifepristone dynamics (Teva and others have launched generics — though Corcept's rare-disease use is highly specialized and the generic-substitution risk has been less than feared), and pipeline progression. Risks/competitors: generic mifepristone competition (a structural overhang on Korlym pricing/share, partly mitigated by the rare-disease specialty channel), the relacorilant transition risk (if Cushing is approved, Corcept must successfully transition patients — a transition discount could compress revenue temporarily), the broader Cushing syndrome treatment landscape — Recordati's Isturisa (osilodrostat) for Cushing-disease (the pituitary-cortisol-secretion-driven form), various older agents (ketoconazole, etomidate, metyrapone — older off-label generics), and possible new entrants. Comp set: in Cushing/rare-endocrinology — Recordati (REC.MI, Italian, Isturisa), Strongbridge Biopharma legacy / Xeris Biopharma (XERS), Crinetics Pharmaceuticals (CRNX, also a Cushing pipeline), Sparrow Pharmaceuticals (private); in specialty biopharma — Insmed (INSM), Vanda (VNDA), Crinetics (CRNX), Argenx (ARGX), Ultragenyx (RARE).

The Relacorilant Pipeline: Cushing's Transition Plus the ROSELLA Ovarian-Cancer Readout

The second deep-dive is the relacorilant pipeline — Corcept's next-generation cortisol modulator and the source of substantial pipeline value beyond Korlym. Relacorilant: an oral, once-daily, selective glucocorticoid antagonist designed to block GR without antagonizing the progesterone receptor (PR) — eliminating the progesterone-related effects that constrain mifepristone's commercial use; selective GR antagonism is a long-pursued mechanism that's potentially applicable across multiple disease areas. The GRACE Phase 3 trial (Cushing syndrome): a randomized placebo-controlled trial of relacorilant in adults with endogenous Cushing syndrome with hyperglycemia and/or hypertension; positive top-line results delivered (statistically significant on glucose, blood-pressure, weight and other endpoints; clean safety profile); NDA filed; FDA review under way with a potential 2026 PDUFA decision; if approved, relacorilant becomes the franchise-defining drug — replacing Korlym with a cleaner-safety-profile, expanded-commercial-breadth selective antagonist, with IP protection presumably extending well into the 2030s+. The ROSELLA Phase 3 trial (platinum-resistant ovarian cancer): a randomized Phase 3 trial of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in platinum-resistant ovarian cancer (PROC) — a tough-to-treat oncology setting where new active agents are scarce; the mechanism rationale is that glucocorticoid signaling in tumor cells promotes resistance to taxane chemotherapy — and relacorilant's GR antagonism re-sensitizes tumors to nab-paclitaxel; Phase 2 data showed encouraging activity on progression-free survival; ROSELLA is the registrational Phase 3 with data readout expected in 2026 — a positive result would open a multi-billion-dollar oncology indication and transformatively expand Corcept's TAM. Other pipeline programs: relacorilant in other oncology settings (ovarian + selected solid tumors), dazucorilant (an earlier-stage selective GR antagonist with a different profile) for ALS and other indications, and additional cortisol-modulator molecules in earlier development for metabolic disease, neurology, and oncology. FY2025 dynamics: GRACE NDA under FDA review, ROSELLA Phase 3 trial completing/data maturing, earlier-stage pipeline progressing, R&D investment intense. FY2026 catalyst: the GRACE NDA decision (likely first H1 2026 PDUFA) — the major near-term commercial catalyst (transitioning Cushing franchise), the ROSELLA Phase 3 readout — the major asymmetric pipeline-value event, pipeline progression on other indications, and possible business-development activity (licensing, partnerships, M&A). Risks: ROSELLA Phase 3 failure (mixed Phase 2 data + ovarian cancer is a tough setting — meaningful risk), GRACE NDA setback (FDA could require additional information), relacorilant-transition execution from Korlym, pipeline-development risk on earlier programs, and the broader specialty-pharma capital-allocation discipline. Comp set: on selective GR antagonist — Corcept is effectively alone in late-stage development; on Cushing — Recordati (REC.MI), Crinetics (CRNX); on PROC oncology — GSK (GSK, Zejula), AstraZeneca (AZN, Lynparza), Genentech (Tecentriq), ImmunoGen (now AbbVie, Elahere)** for combination/PROC settings; broader specialty pharma — Insmed (INSM), Krystal Biotech (KRYS), Argenx (ARGX), Ultragenyx (RARE).

Capital Position + Balance Sheet

Corcept runs a net-cash, shareholder-return-rich balance sheet — an unusual structure for a specialty biopharma. The company pays no dividend (and not near-term — cash to R&D + pipeline + buybacks), conducts aggressive opportunistic share buybacks (the diluted share count has fallen from selected various aggregate ~120M+ toward ~100-105M, with multi-year repurchase programs consistently executed), and holds substantial net cash (selected various aggregate ~$450-600M+ of cash and short-term investments with no meaningful debt — Corcept has historically operated debt-free), supporting both pipeline R&D investment and capital return. Free-cash-flow conversion is excellent (Korlym is a high-margin specialty drug with low SG&A overhead — strong cash generation). Capital priorities: (1) fund R&D — particularly the relacorilant Phase 3 programs and broader pipeline, (2) aggressive share buybacks compounding EPS, (3) maintain net cash for strategic flexibility, (4) potential bolt-on M&A or business development if the right asset emerges. The principal balance-sheet considerations are the relacorilant-pipeline-driven R&D spending pace, cash deployment for buybacks vs M&A vs balance-sheet preservation, and the eventual transition from Korlym to relacorilant (no dividend or major buybacks would be at risk during the transition, but the strong financial position supports it).

Key Core Metrics

Revenue: selected various aggregate ~$740-820M FY2025 (~12-15% growth)
Adjusted EBITDA: selected various aggregate ~$160-220M FY2025
Adjusted EPS: selected various aggregate ~$1.30-1.65 FY2025 (non-GAAP)
GAAP EPS: ~$0.75-1.00 (heavy R&D investment compresses GAAP)
Korlym (mifepristone) revenue: ~$700M+ annual (entirety of commercial revenue; ~12-15% growth)
Korlym indication: hyperglycemia in endogenous Cushing syndrome (FDA approved Feb 2012)
Korlym pricing: ~$120-180K+ per patient-year (specialty pricing)
Korlym gross margin: ~95%+
Patient-finder initiative: Corcept-funded screening programs identifying undiagnosed Cushing patients
Endogenous Cushing syndrome US: ~20,000-30,000+ diagnosed patients (likely many more undiagnosed)
Generic mifepristone: Teva and others have launched generics; structural overhang on Korlym pricing/share (mitigated by specialty channel)
Relacorilant: oral once-daily selective glucocorticoid antagonist (no progesterone effects vs mifepristone)
GRACE Phase 3 (relacorilant in Cushing): positive top-line; NDA filed/under FDA review; potential 2026 approval
ROSELLA Phase 3 (relacorilant + nab-paclitaxel in platinum-resistant ovarian cancer): registrational; data expected 2026 (major binary)
Other pipeline: dazucorilant (selective GR antagonist) for ALS; other earlier-stage cortisol-modulator programs
Cash + short-term investments: selected various aggregate ~$450-600M+ FY2025 (no meaningful debt — net-cash)
Net debt: net cash
Credit profile: implicitly investment-grade-equivalent (unrated)
Dividend: none; cash to R&D + buybacks + balance-sheet preservation
Buybacks: aggressive ongoing; ~100-105M diluted shares (down from ~120M+ historic peak)
Capex: minimal (no manufacturing — contracted out); excellent FCF conversion
Capital allocation: R&D (relacorilant pipeline) → aggressive buybacks → maintain net cash → potential bolt-on M&A
Co-founder & CEO: Joseph Belanoff (President & CEO, ~27+ year tenure since founding 1998)
Co-founder: Alan Schatzberg (researcher)

Market Evaluation

At roughly ~$50-100 per share on ~100-105M shares, Corcept Therapeutics carries an equity value of selected various aggregate ~$5-10B (and an enterprise value of selected various aggregate ~$4.5-9.5B given the net-cash position), which on FY2025 cash flow is roughly ~30-65x P/E (broad range reflecting non-GAAP vs GAAP and the binary nature of the pipeline catalysts), ~25-50x EV/EBITDA — a premium specialty-pharma multiple reflecting (a) the relacorilant pipeline optionality (especially ROSELLA), (b) Korlym's high-margin franchise persistence, (c) the IP-protection extension via relacorilant, and (d) the strong balance sheet. The comp set: in Cushing — Recordati (REC.MI, Italian, Isturisa), Crinetics Pharmaceuticals (CRNX), Xeris Biopharma (XERS); in specialty pharma — Insmed (INSM), Vanda (VNDA), Argenx (ARGX), Ultragenyx (RARE), Krystal Biotech (KRYS), BridgeBio (BBIO), Apellis (APLS); in oncology adjacencies for ROSELLA — GSK (GSK), AstraZeneca (AZN), AbbVie (ABBV, ImmunoGen/Elahere) in PROC. FY2026 base case: selected various aggregate ~$840-940M+ revenue + ~$1.50-1.95 adj. EPS + Korlym continued growth + relacorilant Cushing NDA decision pending + ROSELLA Phase 3 readout (binary) + continued buybacks + cash building. Bull case: selected various aggregate ~$900-1.05B+ revenue + ~$1.75-2.40+ adj. EPS on relacorilant Cushing approved (initial transition begins, IP extended), ROSELLA Phase 3 positive (transformative — multi-billion-dollar oncology indication unlocked), Korlym continued growth in the meantime, generic-mifepristone impact modest, aggressive buybacks shrinking the share count, possible accretive M&A, and a substantial multiple re-rating. Bear case: selected various aggregate ~$650-760M revenue + ~$0.85-1.25 adj. EPS on ROSELLA Phase 3 failure (the major asymmetric downside — eliminates oncology optionality and pressures relacorilant-platform value), GRACE NDA setback (delaying the Korlym-to-relacorilant transition), accelerated generic-mifepristone share losses (compressing Korlym faster than expected), pipeline-development setbacks, and a multiple compression. The thesis turns on the Korlym commercial pipeline (Cushing-patient identification + prescription growth + generic-mifepristone defense + relacorilant transition prep) plus the relacorilant pipeline (GRACE Cushing approval + ROSELLA Phase 3 readout + IP extension + broader indication exploration) plus a net-cash balance sheet plus aggressive buybacks plus Joseph Belanoff's continued multi-decade co-founder-led stewardship of the cortisol-modulator platform.